EuroSCORE II and the STS score are more accurate in transapical than in transfemoral transcatheter aortic valve implantation†

Kofler, Markus; Reinstadler, Sebastian Johannes; Stastny, Lukas; Dumfarth, Julia; Reindl, Martin; Wachter, Kristina; Rustenbach, Christian; Müller, Silvana; Feuchtner, Gudrun; Friedrich, Guy; Metzler, Bernhard; Grimm, Michael; Bonaros, Nikolaos; Baumbach, Hardy

doi:10.1093/icvts/ivx343

Cited by 15 publications

(6 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The sample size did not allow for subgroup analysis to differentiate outcome in either diabetic or non-diabetic patients and this question should be addressed in a specifically designed study. The sample size could also explain that the trend observed between the risk of MAEs and the Euroscore value did not reach the statistical significance although a weak but statistically significant association was reported between Euroscore and mortality after TAVI in some previously published studies [35, 36]. Second, glycemic variability was not determined using a continuous monitoring system and could be underestimated [3].…”

Section: Discussionmentioning

confidence: 99%

Impact of post-procedural glycemic variability on cardiovascular morbidity and mortality after transcatheter aortic valve implantation: a post hoc cohort analysis

Besch

Pili-Floury

Morel

et al. 2019

Cardiovasc Diabetol

View full text Add to dashboard Cite

BackgroundGlycemic variability is associated with worse outcomes after cardiac surgery, but the prognosis value of early glycemic variability after transcatheter aortic valve implantation is not known. This study was therefore designed to analyze the prognosis significance of post-procedural glycemic variability within 30 days after transcatheter aortic valve implantation.MethodsA post hoc analysis of patients from our center included in the FRANCE and FRANCE-2 registries was conducted. Post-procedural glycemic variability was assessed by calculating the mean daily δ blood glucose during the first 2 days after transcatheter aortic valve implantation. Major complications within 30 days were death, stroke, myocardial infarction, acute heart failure, and life-threatening cardiac arrhythmias.ResultsWe analyzed 160 patients (age (median [interquartile] = 84 [80–88] years; diabetes mellitus (n) = 41 (26%) patients; logistic Euroscore = 20 [12–32]). The median value of mean daily δ blood glucose was 4.3 mmol l−1. The rate of major complications within 30 days after procedure among patients with the lowest quartile of glycemic variability was 12%, increasing from 12 to 26%, and 39% in the second, third, and fourth quartiles, respectively. In multivariate analysis, glycemic variability was independently associated with an increased risk of major complications within 30 days after the procedure (odds ratio [95% CI] = 1.83 [1.19–2.83]; p = 0.006).ConclusionsThis study showed that post-procedural glycemic variability was associated with an increased risk of major complications within 30 days after transcatheter aortic valve implantation.Trial registration Clinical trial registration number https://www.clinicaltrials.gov/; identifier: NCT02726958; date: April 4th, 2016

show abstract

Section: Discussionmentioning

confidence: 99%

Impact of post-procedural glycemic variability on cardiovascular morbidity and mortality after transcatheter aortic valve implantation: a post hoc cohort analysis

Besch

Pili-Floury

Morel

et al. 2019

Cardiovasc Diabetol

View full text Add to dashboard Cite

show abstract

“…Holiski et al, por ejemplo, encontraron una AUC de 0.86 para EuroSCORE II y de 0.64 para STS en pacientes alemanes 11 . Kofler et al encontraron una AUC de 0.664 y 0.628 de los puntajes STS y EuroSCORE II para la predicción de mortalidad 10 . De manera similar, Borde et al encontraron que tanto el EuroSCORE II como el STS predijeron pobremente mortalidad (AUC: 0.69 de EusoSCORE y 0.65 de STS) 22 .…”

Section: Discussionunclassified

“…Si bien estos modelos han sido validados externamente, su desempeño no es el esperado en tales validaciones y se han reportado áreas bajo la curva (AUC) de 0.628-0.800 [7][8][9] . Por lo tanto, es fundamental evaluar si los modelos existentes son buenos predictores y se ajustan a la realidad de cada hospital, ya que en algunos casos los modelos de predicción no han sido tan buenos como se espera 10,11 y porque se ha demostrado que la calibración de los modelos de predicción de mortalidad cardiovascular se ha deteriorado con el tiempo 12 .…”

Section: Introductionunclassified

Capacidad del ArgenSCOR E para predecir mortalidad en pacientes mexicanos sometidos a cirugía cardiovascular abierta

Trujillo-Malo¹,

Gudiño-Carballo²,

Navarrete-Sandoval³

2021

RHJM

View full text Add to dashboard Cite

permiten estimar la mortalidad asociada a cirugía cardiovascular, pero su desempeño es distinto entre poblaciones o estudios. Objetivo: Comparar la capacidad de EuroSCORE II, STS y ArgenSCORE para predecir mortalidad en pacientes mexicanos sometidos a cirugía cardiovascular abierta. Metodología: Se realizó un estudio observacional de cohorte prospectivo en pacientes que fueron sometidos a cirugía cardiovascular en el Hospital General Ignacio Zaragoza ingresados a la unidad de cuidados intensivos

show abstract

“…Рентгенэндоваскулярная методика повторной имплантации биопротеза в аортальную позицию по методике «клапан в клапан» является рациональным вариантом лечения, особенно у пожилых пациентов с высоким хирургическим риском в связи с имеющейся сопутствующей патологией [10]. Использование известных в кардиохирургии шкал хирургического риска (EuroSCORE, STS-score) [11,12] позволило не только прогнозировать вероятность развития осложнений, но и предупредить их в послеоперационном периоде у описываемой нами пациентки высокого риска и, воздержавшись от хирургического репротезирования АК, успешно провести транскатетерное вмешательство.…”

Section: клиническое наблюдениеunclassified

Valve-in-valve transcatheter aortic valve replacement on a self-expandable nitinol frame due to degeneration of primary bioprosthetic valve cusps. Clinical case of a high-risk surgical female patient

Коков

Соколов

Parkhomenko

et al. 2020

RJTAO

View full text Add to dashboard Cite

Introduction. We present the clinical observation of a 72-year-old female patient with high surgical risk and structural degeneration of a bioprosthetic aortic valve (AV) cusps in the form of stenosis, accompanied by severe dysfunction. Transcatheter implantation of bioprosthesis Medtronic CoreValve™ Evolut™ R-23 was performed using the valve-in-valve technique. The choice of minimally invasive treatment tactics is substantiated, a preoperative examination algorithm and a specific bioprosthesis model for such intervention are provided. Materials and methods. Imaging – echocardiography (Echo), electrocardiography, multispiral computed tomography, coronary angiography. Bioprosthetic valve calcification and stenosis with critical parameters of the bioprosthetic AV peak pressure gradient according to Echo data were the indications for minimally invasive surgery. Results. Dynamic observation revealed a progressive deterioration in the function of the previously implanted bioprosthetic heart valve in the aortic position, and a critical deterioration in the patient’s condition. After additional examination of the patient and selection of a new prosthesis, valve-in-valve transcatheter aortic valve replacement was done. The positive dynamics of the general state of the patient was noted in the early postoperative period. Echo data showed that the bioprosthetic AV peak systolic pressure gradient decreased from 90 to 29 mmHg, average gradient – from 42 to 19 mmHg. Conclusion. The minimally invasive valve-in-valve transcatheter aortic valve replacement used to correct the dysfunction of a bioprosthetic AV that was previously implanted during an open surgery was shown to be safe and effective and can be considered as one of the options for repeat valve replacement.

show abstract

EuroSCORE II and the STS score are more accurate in transapical than in transfemoral transcatheter aortic valve implantation†

Abstract: The EuroSCORE II and the STS score were independent predictors of 30-day and cumulative mortality rates in patients undergoing TAVI. The EuroSCORE II and the STS score were associated with 30-day mortality and mortality during follow-up period only in TA TAVI.

Cited by 15 publications

References 24 publications

Impact of post-procedural glycemic variability on cardiovascular morbidity and mortality after transcatheter aortic valve implantation: a post hoc cohort analysis

Impact of post-procedural glycemic variability on cardiovascular morbidity and mortality after transcatheter aortic valve implantation: a post hoc cohort analysis

Capacidad del ArgenSCOR E para predecir mortalidad en pacientes mexicanos sometidos a cirugía cardiovascular abierta

Valve-in-valve transcatheter aortic valve replacement on a self-expandable nitinol frame due to degeneration of primary bioprosthetic valve cusps. Clinical case of a high-risk surgical female patient

Contact Info

Product

Resources

About